Udenafil FDA Approval Status
Last updated by Judith Stewart, BPharm on July 2, 2020.
FDA Approved: No
Generic name: udenafil
Company: Mezzion Pharma Co. Ltd.
Treatment for: Single Ventricle Heart Disease
Udenafil is a long acting, highly selective phosphodiesterase-5 inhibitor in development for the treatment of patients who have undergone the Fontan operation for single ventricle heart disease.
Development timeline for udenafil
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
